Immunotherapy has achieved great success recently and opened a new avenue for anti-
tumor treatment. Programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) …

Leukemia cells prevent immune system from clearing tumor cells by inducing the
immunosuppression of the bone marrow (BM) microenvironment. In recent years, further …

The intestinal microbiota in allogeneic bone marrow transplant (allo-BMT) recipients
modulates graft-versus-host disease (GVHD), a systemic inflammatory state initiated by …

Mounting an effective immune response against cancer requires the activation of innate and
adaptive immune cells. Metastatic melanoma is the most aggressive form of skin cancer …

Group 3 innate lymphoid cells (ILC3s) control the formation of intestinal lymphoid tissues
and play key roles in intestinal defense. They express neuropeptide vasoactive intestinal …

Adoptive therapy with ex vivo–expanded genetically modified antigen-specific T cells can
induce remissions in patients with relapsed/refractory cancer. The clinical success of this …

Inflammation in the bone marrow (BM) microenvironment is a constitutive component of
leukemogenesis in acute myeloid leukemia (AML). Current evidence suggests that both …

A paucity of effector T cells within tumors renders pancreatic ductal adenocarcinoma (PDAC)
resistant to immune checkpoint therapies. While several under-development approaches …

Introduction The curative basis of allogeneic hematopoietic stem cell transplantation (HSCT)
relies in part upon the graft versus leukemia (GvL) effect, whereby donor immune cells …

Vasoactive intestinal polypeptide (VIP), an anti-inflammatory neuropeptide with pleiotropic
cardiovascular effects, induces differentiation of hematopoietic stem cells into regulatory …